Related Experiment Video
Updated: Oct 29, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting
Douglas S Corwin1, Peter T Ender2, Nitasa Sahu1
1Section of Pulmonary and Critical Care, Department of Medicine, St Luke's University Health Network, Bethlehem, Pennsylvania, USA.
Abstract:
Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.
Related Concept Videos
Antimicrobial Effectiveness
Vaccinations
Bioequivalence studies: Biowaivers
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

